CCXI Key Stats
- Biotech Stock Mailbag: 2013 Clinical Trials Calendar Jun 7
- ChemoCentryx to Present at Two Upcoming Healthcare Conferences and Ring Opening ... Jun 5
- ChemoCentryx Announces Appointment of Health Care Insurance Executive Ira Klein,... May 28
- CHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers... May 28
- Nasdaq stocks posting largest volume increases May 24
- InPlay: ChemoCentryx announces Phase I Data with CCX507, co's new generation ora... May 21
- ChemoCentryx Announces Phase I Data With CCX507, Company's New Generation Orally... May 21
- ChemoCentryx to Host Analyst Day GlobeNewswire May 15
- Wider-than-Expected Loss at ChemoCentryx May 14
- CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condi... May 14
CCXI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Chemocentryx is up 4.05% over the last year vs S&P 500 Total Return up 25.82%, ARCA biopharma down 56.19%, and Dyax Corporation up 64.80%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CCXI
Pro Report PDF for CCXI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CCXI Pro Report PDF
Pro Strategies Featuring CCXI
Did Chemocentryx make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.